Retatrutide
LY3437943, triple GIP/GLP-1/glucagon receptor agonist
A single-molecule triple agonist at the GIP, GLP-1 and glucagon receptors — the most-discussed metabolic research peptide of the current cycle.
Scan the QR code on your vial, or type the batch number, and you get the analytical data for the exact vial you received.
Verify your vial →The C-terminal hGH(177-191) fragment modified with a tyrosine cap, studied for lipolytic activity without the glucose effects of full-length GH.
Price is per single sealed vial, in USD. Buying several — volume pricing.
| Vial strength | Price | |
|---|---|---|
| 2mg | $95.20 | Order 2mg |
| 5mg | $190.40 | Order 5mg |
| 10mg | $347.20 | Order 10mg |
Links open peer-reviewed sources on PubMed. These are provided so you can read the primary literature yourself. Citing a study is not a claim that this compound is safe or effective for any use in humans.
LY3437943, triple GIP/GLP-1/glucagon receptor agonist
A single-molecule triple agonist at the GIP, GLP-1 and glucagon receptors — the most-discussed metabolic research peptide of the current cycle.
LY3298176, dual GIP/GLP-1 receptor agonist
A unimolecular dual agonist of the GIP and GLP-1 receptors, and the compound behind the SURMOUNT and SURPASS trial programmes.
TH9507, trans-3-hexenoyl-GHRH(1-44)
A stabilised GHRH(1-44) analog and the only GH-axis compound with regulatory approval specifically for reducing visceral adipose tissue.
This website sells laboratory research chemicals. Everything on it is intended for qualified researchers and is not for human or veterinary consumption.
We are sorry — you must be at least 21 years old to view this site. Please close this window.
By entering you confirm you are at least 21 years of age, that you will use all products for laboratory research purposes only, and that you accept our Terms of Sale, Privacy Policy and Research Disclaimer.